Suppr超能文献

微小RNA在严重肢体缺血诊断与治疗中的应用

miRNA in the Diagnosis and Treatment of Critical Limb Ischemia.

作者信息

Popescu Alexandra Ioana, Rață Andreea Luciana, Vlad Daliborca, Vlad Cristian, Popescu Roxana, Onofrei Ramona Roxana, Morelli Marialuisa, Pantea Stelian, Barac Sorin

机构信息

Pharmacology Department, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.

Surgical Emergencies Department, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.

出版信息

Biomedicines. 2024 Sep 4;12(9):2026. doi: 10.3390/biomedicines12092026.

Abstract

Chronic threatening limb ischemia of the inferior limbs (CLTI) is the final stage of peripheral arterial disease (PAD) and is one of the most feared atherosclerotic manifestations because if left untreated, in time, it can lead to amputation. Although there are currently numerous treatment techniques, both open and endovascular, it is a pathology that has no underlying treatment. Therefore, current studies are very much focused on new therapeutic possibilities that can be applied in the early stages of the atherosclerotic process. In numerous studies in the literature, miRNAs have been identified as important markers of atherosclerosis. The present study aims to identify the expression of three miRNAs-, -in patients with chronic limb-threatening ischemia in the pre- and post-revascularization periods. The aim of the study is to identify whether these three markers play a role in critical ischemia and whether they have the potential for future use in new treatments of this pathology.

摘要

下肢慢性威胁肢体缺血(CLTI)是外周动脉疾病(PAD)的终末期,是最可怕的动脉粥样硬化表现之一,因为如果不及时治疗,可能会导致截肢。尽管目前有许多开放和血管腔内治疗技术,但这是一种尚无根本治疗方法的病症。因此,当前的研究非常关注可应用于动脉粥样硬化进程早期阶段的新治疗可能性。在文献中的众多研究中,微小RNA(miRNAs)已被确定为动脉粥样硬化的重要标志物。本研究旨在确定三种miRNA在慢性肢体威胁性缺血患者血管再通术前和术后的表达情况。该研究的目的是确定这三种标志物是否在严重缺血中起作用,以及它们是否具有在这种病症的新治疗方法中未来应用的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f694/11428243/9bbdf9bd2775/biomedicines-12-02026-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验